Key result
Integrated analysis identifies circFoxO1 as a regulator of pathological cardiac hypertrophy.
Answers are grounded in this paper and cite their sources.
circRNA roles in CHT models remain exploratory; leaves open therapeutic targeting pending functional validation.
Pathological Cardiac Hypertrophy (CHT) is a maladaptive response that can lead to heart failure and increase the risk of severe cardiovascular events. However, the molecular mechanisms underlying CHT remain incompletely understood, and effective targeted therapies are still limited in clinical practice. Circular RNAs (circRNAs) emerge as important epigenetic regulators in cardiovascular biology, yet their roles in CHT remain insufficiently characterized. In this study, we combined transcriptomic analysis with in vitro and in vivo experimental models to identify functional circRNAs associated with CHT. Differential expression analysis of the GSE148602 dataset, coupled with machine-learning-assisted prioritization, highlighted
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied Pathological Cardiac Hypertrophy. circFoxO1 was evaluated on Identification of functional circRNAs associated with CHT. Integrated bioinformatics analysis and experimental validation revealed circFoxO1 as a regulator of pathological cardiac hypertrophy.
Synapse has enriched 10 related papers. Consider them for comparative context: